These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2907535)

  • 1. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results.
    Vincent-Viry M; Deshayes S; Mothe O; Siest G; Galteau MM
    J Pharm Pharmacol; 1988 Oct; 40(10):695-700. PubMed ID: 2907535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9-mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine.
    Hietanen E; Malaveille C; Camus AM; Béréziat JC; Brun G; Castegnaro M; Michelon J; Idle JR; Bartsch H
    Drug Metab Dispos; 1986; 14(1):118-26. PubMed ID: 2868854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defective bile acid transport in an animal model of defective debrisoquine hydroxylation.
    Reichen J; Krähenbühl S; Küpfer A; Sägesser H; Karlaganis G
    Biochem Pharmacol; 1986 Mar; 35(5):753-9. PubMed ID: 3954785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine.
    Castegnaro M; Bartsch H; Bereziat JC; Arvela P; Michelon J; Broussolle L
    Xenobiotica; 1989 Feb; 19(2):225-30. PubMed ID: 2786290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
    Muralidharan G; Midha KK; McKay G; Hawes EM; Inaba T
    Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of neuroleptics on debrisoquine oxidation in man.
    Syvälahti EK; Lindberg R; Kallio J; De Vocht M
    Br J Clin Pharmacol; 1986 Jul; 22(1):89-92. PubMed ID: 2874826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
    Al-Dabbagh SG; Idle JR; Smith RL
    J Pharm Pharmacol; 1981 Mar; 33(3):161-4. PubMed ID: 6116757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains.
    Küpfer A; Al-Dabbagh SG; Ritchie JC; Idle JR; Smith RL
    Biochem Pharmacol; 1982 Oct; 31(20):3193-9. PubMed ID: 7150348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
    Alván G; Grind M; Graffner C; Sjöqvist F
    Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man.
    Zysset T; Zeugin T; Küpfer A
    Biochem Pharmacol; 1988 Aug; 37(16):3155-60. PubMed ID: 3401246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
    Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations.
    von Bahr C; Birgersson C; Morgan ET; Eriksson O; Göransson M; Spina E; Woodhouse K
    Xenobiotica; 1986 May; 16(5):391-400. PubMed ID: 3739365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereoselectivity of the 4-hydroxylation of debrisoquine in man, detected by gas chromatography/mass spectrometry.
    Meese CO; Fischer C; Eichelbaum M
    Biomed Environ Mass Spectrom; 1988 Jan; 15(2):63-6. PubMed ID: 3349209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.
    Saner H; Gurtner HP; Preisig R; Küpfer A
    Eur J Clin Pharmacol; 1986; 31(4):437-42. PubMed ID: 3816924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
    Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
    Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
    Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
    Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats.
    Guttendorf RJ; Kostenbauder HB; Wedlund PJ
    Drug Metab Dispos; 1991; 19(1):251-6. PubMed ID: 1673410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.